22 research outputs found
Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation:Temporal trends 2011-2015 in Denmark
Among atrial fibrillation (AF) patients, Danish nationwide registries (2011â2015) were used to examine temporal trends of initiation patterns of oral anticoagulation (OAC) treatment according to age. Overall, 43,299 AF patients initiating vitamin K antagonists (VKA) (42%), dabigatran (29%), rivaroxaban (13%), or apixaban (16%) were included with mean age (SD) 72.1 (11.3), 71.5 (11.0), 74.3 (11.1), and 75.3 (11.1) years, respectively. Patients aged âĽ85 years comprised 15%. Trend tests showed increase in patients âĽ85 years initiating OAC (pâ<â0.0001). VKA usage decreased from 92% to 24% (pâ<â0.0001). This decrease was independent of age. Dabigatran was the most common non-VKA OAC (NOAC) (40% users), but usage decreased from 2014 until study end (6%) (pâ<â0.0001). Apixaban was the most used OAC at study end (41%), in particular among those âĽ85 years (44%). Compared with patients aged <65 years, the odds ratios associated with initiating VKA, dabigatran, rivaroxaban, or apixaban for patients aged âĽ85 years were 0.81 (95% CI 0.75â0.86), 0.65 (95% CI 0.60â0.70), 1.52 (95% CI 1.38â1.67), and 2.09 (95% CI 1.89â2.30), respectively. In conclusion, substantial increase in NOAC usage has occurred. Increasing age was associated with upstart of rivaroxaban or apixaban with reference to age <65 within the specific agent
Generalization of a Real-Analysis Result to a Class of Topological Vector Spaces
In this paper, we generalize an elementary real-analysis result to a class of
topological vector spaces. We also give an example of a topological vector
space to which the result cannot be generalized.Comment: 6 pages, no figure